Latest News and Press Releases

FDA approves UZEDY® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I...

New York, USA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Bipolar Disorder Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight The bipolar disorder clinical trial...

Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The "Bipolar Disorder Market - A Global and Regional Analysis: Focus on Class Type and Country Analysis - Analysis and Forecast, 2025-2035" report has been...

Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Psychiatry Collaboration and Licensing Deals 2019-2025" report has been added to ResearchAndMarkets.com's offering.Psychiatry Collaboration and...

Dublin, April 30, 2025 (GLOBE NEWSWIRE) -- The "Bipolar Disorder (Manic Depression)- Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering. The report offers an extensive...

Washington, D.C, March 12, 2025 (GLOBE NEWSWIRE) -- Today, Breakthrough Discoveries for thriving with Bipolar Disorder (BD²) announced four new national institutions to receive $2.3 million each to...

Dublin, Sept. 30, 2024 (GLOBE NEWSWIRE) -- The "Psychiatry Collaboration and Licensing Deals 2019-2024" report has been added to ResearchAndMarkets.com's offering.Psychiatry Collaboration and...

Washington D.C., Sept. 26, 2024 (GLOBE NEWSWIRE) -- BD²: Breakthrough Discoveries for thriving with Bipolar Disorder today announced its second installment of Discovery Research grants, totaling...

Dublin, July 31, 2024 (GLOBE NEWSWIRE) -- The "Global Mental Health Screening Market Size, Share & Trends Analysis Report by Component (Hardware, Software), Application (Cognitive, Behavioral),...

Washington, DC, July 18, 2024 (GLOBE NEWSWIRE) -- BD²: Breakthrough Discoveries for Thriving with Bipolar Disorder today announced its second call for applications for clinic sites to join the BD²...